human
TASK: Your task is to answer biomedical questions using the given abstract. Only output yes, no, or maybe as answer.
INPUT: ['To investigate the possible mechanism by which adiponectin influences the osteoclastogenesis.', 'Human osteoblasts were cultured in vitro and adiponectin of the concentrations 0, 3, 10, and 30 microg/ml were added for 48 hours to investigate the dose-dependent effect on the mRNA and protein expression of osteoprotegerin (OPG) in osteoblasts, and adiponectin of the concentrations 0 or 30 microg/ml was added for 0-48 hours to investigate the time-dependent effect. Fluorescent quantitation PCR and ELISA were used to detect the expression of OPG and receptor activator of nuclear factor-kappaB ligand (RANKL). Other human osteoblasts were cultured with CD14 + peripheral blood mononuclear cells (PBMCs), and incubated together with adiponectin of the concentration of 30 microg/ml for 14 days, and then stained by antitartaric acid phosphatase, a marker enzyme of osteoclast.', 'The expression levels of mRNA and protein of OPG in osteoblasts were 100% +/- 9%, 68% +/- 7%, 47% +/- 8%, and 30% +/- 5%, and (9.2 +/- 0.3), (6.6 +/- 0.4), (4.1 +/- 0.4), and (2.6 +/- 0.4) ng/ml respectively after incubation with adiponectin of the concentrations of 0, 3, 10, and 30 microg/ml for 48 hours. The mRNA and protein expression levels of RANKL were 100% +/- 5%, 165% +/- 8%, 213% +/- 6%, and 316% +/- 10%, and (1.3 +/- 0.2), (2.1 +/- 0.1), (2.3 +/- 0.2), and (2.8 +/- 0.1) ng/ml respectively. Adiponectin inhibited the osteoblast OPG expression and promoted the osteoblast RANKL expression dose- and time-dependently (P < 0.05). Adiponectin induced the osteoclast formation in the coculture systems of osteoblast and PBMCs systems.'] Does [ Adiponectin regulate the expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand in human osteoblast ]?
OUTPUT:

agent
yes
TASK: Your task is to answer biomedical questions using the given abstract. Only output yes, no, or maybe as answer.
INPUT: ['To investigate the possible mechanism by which adiponectin influences the osteoclastogenesis.', 'Human osteoblasts were cultured in vitro and adiponectin of the concentrations 0, 3, 10, and 30 microg/ml were added for 48 hours to investigate the dose-dependent effect on the mRNA and protein expression of osteoprotegerin (OPG) in osteoblasts, and adiponectin of the concentrations 0 or 30 microg/ml was added for 0-48 hours to investigate the time-dependent effect. Fluorescent quantitation PCR and ELISA were used to detect the expression of OPG and receptor activator of nuclear factor-kappaB ligand (RANKL). Other human osteoblasts were cultured with CD14 + peripheral blood mononuclear cells (PBMCs), and incubated together with adiponectin of the concentration of 30 microg/ml for 14 days, and then stained by antitartaric acid phosphatase, a marker enzyme of osteoclast.', 'The expression levels of mRNA and protein of OPG in osteoblasts were 100% +/- 9%, 68% +/- 7%, 47% +/- 8%, and 30% +/- 5%, and (9.2 +/- 0.3), (6.6 +/- 0.4), (4.1 +/- 0.4), and (2.6 +/- 0.4) ng/ml respectively after incubation with adiponectin of the concentrations of 0, 3, 10, and 30 microg/ml for 48 hours. The mRNA and protein expression levels of RANKL were 100% +/- 5%, 165% +/- 8%, 213% +/- 6%, and 316% +/- 10%, and (1.3 +/- 0.2), (2.1 +/- 0.1), (2.3 +/- 0.2), and (2.8 +/- 0.1) ng/ml respectively. Adiponectin inhibited the osteoblast OPG expression and promoted the osteoblast RANKL expression dose- and time-dependently (P < 0.05). Adiponectin induced the osteoclast formation in the coculture systems of osteoblast and PBMCs systems.'] Does [ Adiponectin regulate the expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand in human osteoblast ]?
OUTPUT:
